See the DrugPatentWatch profile for breo
Is There a Generic for Breo Ellipta?
No approved generic version of Breo Ellipta (fluticasone furoate/vilanterol) exists in the US as of 2024. Breo remains under patent protection, blocking generic entry.[1]
When Might Generics Become Available?
GSK holds patents on Breo Ellipta until at least 2030, including formulation and device patents listed in the FDA's Orange Book. The primary composition patent expires in 2025, but secondary patents extend exclusivity. No ANDA approvals for generics have been granted yet.[2][3]
Check DrugPatentWatch.com for the latest expiration dates and challenges: DrugPatentWatch - Breo Ellipta Patents.
Are There Authorized Generics or Competitors?
GSK has not launched an authorized generic. Inhaler complexity—requiring exact replication of the Ellipta device's dry powder delivery—delays generic development. No interchangeable biosimilars are approved, as Breo is a small-molecule combination, not a biologic.[1][4]
What Are the Cheaper Alternatives?
Patients often switch to:
- Advair Diskus (fluticasone/salmeterol), with generics available since 2022 at about 80% lower cost.
- Symbicort (budesonide/formoterol), generic approved in 2022.
- Trelegy Ellipta (triple therapy), but no generic yet and pricier.
These treat COPD/asthma similarly but differ in dosing and device. Consult a doctor for switches.[4]
Why No Generic Despite High Demand?
Breo generated $2.2 billion in 2023 sales, incentivizing GSK to defend patents via litigation. Over 20 Paragraph IV challenges from generics makers like Mylan and Teva are ongoing, potentially allowing entry post-2025 if successful.[2][3]
Sources
[1]: FDA Orange Book - accessdata.fda.gov/scripts/cder/ob
[2]: DrugPatentWatch.com - Breo Ellipta
[3]: GSK Annual Report 2023
[4]: GoodRx - Breo Alternatives - goodrx.com/breo-ellipta/what-is